2007 Top 20 Pharmaceutical Companies Report
Pfizer's at the top of the roost, but one hare-brained mega-acquisition by GlaxoSmithKline or Sanofi could topple them. Companies #2-5 are all foreign, but seven of the next eight are based in the U.S.; I have no idea what that's supposed to signify. Demonstrating how tough it is to stay at the top, only four companies in the top 10 reached double-digit sales growth.
The largest increase in revenues was Novartis' $3.3 billion, but almost 30% of that came from its purchase of Chiron. GSK had the greatest "organic" growth, adding $3.0 billion in revenues. Bristol-Myers Squibb and Abbott Laboratories suffered the most last year, shedding $1.4 billion and $1.3 billion in revenues, respectively.
Several companies near the bottom of our list moved up thanks to strategic acquisitions; Bayer's purchase of Schering AG led to the biggest jump by any company on the list, from #20 to #16. Let's hope no one else gets any bright ideas . . .
—Gil Y. Roth, Editor
|Top 20 Pharmaceutical Companies|
|07||Johnson & Johnson||$23,267|
|10||Eli Lilly & Co.||$14,816|
Based on 2006 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
For the online edition, pipeline and patent expiry info is only available for companies #1-5.
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Abbott Laboratories and Boehringer-Ingelheim, by Kristin Brooks.
All pipeline information compiled by Kristin Brooks
Photo courtesy of Bristol-Myers Squibb